BIOEOTCPharmaceutical PreparationsFiscal year ends December 31
Bio Essence Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 14, 2026
$0.42+0.03 (+7.72%)
Close on Oct 19, 2026
- Market cap
- $21.38M
- P/E (TTM)
- 10.5
- Dividend yield
- –
Bio Essence statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Bio Essence | Industry median |
|---|---|---|
| Market Cap | $22.61M | $197.05M |
| Enterprise Value | $22.60M | $106.56M |
| PE Ratio | 10.50 | 20.52 |
| PS Ratio | 7.76 | 3.93 |
| PB Ratio | 9.65 | 2.14 |
| P/OCF Ratio | 21.01 | 13.78 |
Enterprise value
| Measure | Bio Essence | Industry median |
|---|---|---|
| EV / Sales | 7.76 | 2.69 |
| EV / EBITDA | 13.76 | 14.86 |
| EV / EBIT | 14.69 | 19.00 |
Income (trailing twelve months)
| Measure | Bio Essence | Industry median |
|---|---|---|
| Revenue | $2.91M | $57.94M |
| Gross Profit | $2.03M | $90.47M |
| Operating Income | $1.54M | -$21.44M |
| Pretax Income | $1.54M | -$14.45M |
| Net Income | $1.52M | -$22.46M |
| EBITDA | $1.64M | -$16.91M |
| EPS (Diluted) | $0.04 | -$0.83 |
Margins
| Measure | Bio Essence | Industry median |
|---|---|---|
| Gross Margin | 69.7% | 52.3% |
| Operating Margin | 52.9% | -44.5% |
| Pretax Margin | 52.8% | -13.0% |
| Profit Margin | 52.1% | -39.2% |
| EBITDA Margin | 56.4% | -31.3% |
Returns
| Measure | Bio Essence | Industry median |
|---|---|---|
| Return on Assets (ROA) | 73.7% | -41.0% |
| Return on Capital Employed (ROCE) | 64.2% | -37.8% |
Growth
| Measure | Bio Essence | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 416.6% | 6.01% |
| Revenue Growth (3Y CAGR) | 45.1% | 2.25% |
| Revenue Growth (5Y CAGR) | 14.6% | 6.42% |
Balance sheet
| Measure | Bio Essence | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $675 | $62.42M |
| Net Cash (Debt) | $675 | $15.68M |
| Net Cash Per Share | $0.00 | $0.65 |
| Equity (Book Value) | $2.34M | $48.79M |
| Book Value Per Share | $0.04 | $1.36 |
| Tangible Book Value | -$1.05M | $23.06M |
| Working Capital | -$998.52K | $75.77M |
Financial position
| Measure | Bio Essence | Industry median |
|---|---|---|
| Current Ratio | 0.38 | 3.30 |
| Quick Ratio | 0.00 | 2.39 |
Cash flow (trailing twelve months)
| Measure | Bio Essence | Industry median |
|---|---|---|
| Operating Cash Flow | $1.08M | -$12.35M |
Efficiency
| Measure | Bio Essence | Industry median |
|---|---|---|
| Asset Turnover | 1.41 | 0.38 |
| Revenue Per Employee | $727.88K | $398.96K |
| Profits Per Employee | $379.38K | -$732.08K |
| Employee Count | 4 | 73 |
Dividends and yields
| Measure | Bio Essence | Industry median |
|---|---|---|
| Earnings Yield | 6.71% | -21.2% |
Shares
| Measure | Bio Essence | Industry median |
|---|---|---|
| Shares Outstanding | 53,809,000 | 59,128,900 |
| Shares Change (YoY) | 13.0% | 11.1% |
| Shares Change (QoQ) | 15.0% | 0.54% |
| Float | 53,726,900 | 48,744,500 |
| Shares Held by Insiders | 0.15% | 11.8% |
Taxes
| Measure | Bio Essence | Industry median |
|---|---|---|
| Income Tax | $20.25K | $91.50K |
| Effective Tax Rate | 1.32% | 20.6% |
Scores
| Measure | Bio Essence | Industry median |
|---|---|---|
| Graham Number | $0.20 | $17.36 |
| Graham Upside | -52.9% | -45.5% |
| Altman Z-Score | 6.69 | 0.10 |
| Piotroski F-Score | 9 | 4 |
Calculated by StockData from Bio Essence's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.